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Table 1
2004-06 2006-10 2010-13 p (2004-06 vs
2010-13)
Day 0 to +30 42.1% 33.4% 13.8% 0.016
Day +31 to +100 61.9% 30.5% 12.7% <0.001
Day +101 to +180 62.4% 45.7% 19.8% 0.001
Day +181 to +365 26.3% 19.9% 5.0% <0.001
Figure 1. HCV Quantitative RNA PCR HCV viral load in peripheral blood was
monitored by quantitative PCR for HCV RNA weekly. Patient had 7 log10 titer
prior and after UCBT. Titers decreasedw2 log10 fold weekly after initiation of
treatment.
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of neutrophil engraftment by day +30 was 82%, and inci-
dence of grade II-IV aGVHD was 44.2%,
For the different time periods of immune reconstitution,
the rate per 100 person months of bacterial infections
decreased as shown in table 1. Of the BBSIs for each time
period, the proportion of GPC BBSIs decreased (2004-06:56%,
2006-10:53.1%, 2010-13:39.2%, respectively), 2004-06 vs.
2010-13, p¼0.048.
GNR antibiotic resistance increased to levoﬂoxacin (4.4%
from 2004-06 to 17.2% from 2010-2013), decreased to cefe-
pime (13.3% from 2004-06 to 7.7% from 2010-13), and
remained stable to piperacillin-tazobactam (7.7% in 2004-06
to 9.1% from 2010-13). GPC antibiotic resistance to vanco-
mycin increased from 3.4% in 2004-06 to 10.5% in 2010-13.
Lastly, in our multivariate analysis RTC regimen was a
signiﬁcant risk factor for the development of piperacillin-
tazobactam resistance in GNR (OR 4.421, 95% CI 1.331-14.69,
p¼0.015). TRM was signiﬁcantly higher in BBSI patient be-
tween 2004-06 (27.9%) vs. 2010-13 (9.3%) (p¼0.03).
Discussion: Our analysis showed a decrease in BBSI rates
after CLABSI protocol was implemented at our institution
and a signiﬁcant decline in BBSI in the post-CLABSI era. The
proportion of GPC infections decreased over this time period.
However, further investigation on factors associated with
decrease in BBSI in these different time periods is ongoing.
The rise in vancomycin resistance (likely due to its wide-
spread use as empiric antibiotic choice for alloHCT patients
with fever), warrants further investigation.201
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Hepatitis C virus (HCV) infection increases the non-relapse
mortality risk after HSCT. Oral direct-acting antiviral (DAA)
drugs Simeprevir, an NS3/4A protease inhibitor, in combi-
nation with Sofosbuvir, a nucleotide analogue inhibitor of
NS5G polymerase are replacing the standard therapy of
interferon (IFN) and ribavirin (RBV). Here, we present the
ﬁrst case report of a pediatric patient with very high HCV
viral load after an UCBTwhowas treatedwith Sofosbuvir and
Simeprevir. The patient had an early virologic response (EVR)
and developed HCV-speciﬁc CD3+ T cells.
A 4 yr. old girl was referred for relapsed B-lymphoblastic
leukemia in CR3. HCV antibody was negative but nucleic acid
test was positive. HCV RNA PCR was elevated at log 7.2 (Fig1). Genotype was HCV-1a subtype with unfavorable vari-
ants for IL28BS but NS3 genotype was negative. Liver US was
normal and LFT was not signiﬁcantly elevated. Liver biopsy
was negative for ﬁbrosis and cirrhosis but demonstrated
moderate hepatitis.
Patient underwent a single 4 of 6 UCBT (10.6 x107 TNC/kg)
using TBI, ﬂudarabine and cyclophosphamide. GVHD pro-
phylaxis included cyclosporine (CSA) and mycophenolate
mofetil (MMF). Engraftment occurred on D13. Sinusoidal
obstruction syndrome (SOS) developed on D20-33 and
treatedwith deﬁbrotide. HCV treatment was initiated on D75
with Sofosbuvir and Simeprevir. Weekly PCR for HCV RNA
demonstrated w2log decrease (Fig 1) despite remaining on
CSA. Viral speciﬁc immune response to HCV was evaluated
using donor speciﬁc HLA-A restricted tetramer. The patient
was HLA-A*32:01/30:02 and received an UCB with HLA-
A*3:01/30:01. Using HLA-A*03:01 restricted tetrameter for
HCV epitope KLVALGINA, we identiﬁed HCV speciﬁc donor T
cells. CDR3 regions are being sequenced to determine
whether the T cell response is oligoclonal or polyclonal. The
availability of the new, highly effective oral DAA HCV medi-
cation allows for IFN-free therapy and will impact the
treatment for HCV after HSCT. The ability to clear the HCV
and maintain viral remission will signiﬁcantly decrease the
risk of developing cirrhosis, hepatic failure and hepatocel-
lular carcinoma.202
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Background: Despite advances in novel anti-plasma cell
therapies translating to improved outcomes, multiple
Figure 1. Kaplan Meier ﬁgure by AMC recovery by day 100.
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matopoietic cell transplantation (AHCT) though sought as a
potential curative strategy, has not translated to improved
overall survival (OS) owing to a high incidence of transplant
related mortality. The objective of this study was to assess if
monocyte and lymphocyte count recovery at day 100 had
any prognostic value in this population.
Methods: We performed a retrospective analysis of patients
who underwent AHCT for multiple myeloma between 2002
and 2013 at a single institution. The primary endpoint of the
study was day 100 peripheral blood absolute lymphocyte
(ALC) and monocyte count (AMC) post-AHCT on overall
survival (OS). Other patient, disease and transplant related
factors were also evaluated. An ALC >¼ 500/mL and AMC
>¼300/mL were used as cut-offs based on published data. OS
was deﬁned from the time of transplantation to last follow-
up or death due to any cause. OS estimates were determined
using the Kaplan-Meier estimator. Cox proportional hazards
model was used for multivariate analysis.
Results: 78 patients underwent AHCT for MM at our insti-
tution. Patient, disease and transplant characteristics are
reported in Table 1. Eight patients were excluded from the
survival and multivariate analysis owing to death prior to
day 100 or because of missing day 100 counts. On
multivariate analysis, only day 100 AMC <300 /mL was
associated with increased mortality (Table 2). ALC recovery
>¼500/mL at day 100, while signiﬁcant on univariate
analysis, was not signiﬁcant on multivariate analysis. Figure
1 shows the Kaplan-Meier survival ﬁgure for the cohort
that achieved an AMC >¼300 (blue) versus <300 (red),
log-rank p-value <0.0001.
Conclusions: In this heterogeneous cohort of multiple
myeloma patients who underwent AHCT, an AMC recovery of
>¼300/mL was associated with improved survival.Table 1
Characteristic Total, N¼78 (%)
Median age at transplant, years (range) 53 (23-69)
Median time from diagnosis to transplant,
months (range)
12 (7-81)
Gender
-Male 50 (64)
International Staging System
-I 27 (35)
-II 21 (27)
-III 28 (36)
-Missing 2 (2)
Disease Status at Transplant
-sCR, CR or VGPR 25 (32)
-PR 48 (62)
-Stable or Progressive disease 5 (6)
Donor type
-Related* 70 (90)
-Unrelated 8 (10)
Type of transplant
-Myeloablative 11 (14)
-Non-myeloablative 67 (86)
Chronic GVHD
-Present 29 (37)
-Absent 49 (63)
Median follow up of surviving patients,
months (range)
49.4 (2.3e129.3)
Table 2
Multivariate analysis of factors associated with mortality
Variable Relative risk (95% conﬁdence interval) p-value
Day 100 AMC 0.0002
-300/mL 1.0
-<300/mL 4.6 (2.1e10.2)203
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T-Follicular Helper Cells (TFH) interact with B-cells in the
germinal center to support B-cell proliferation, differentia-
tion and immunoglobulin gene class switch. TFH have been
reported to alter B-cell homeostasis in autoimmune diseases
(Morita et al, Immunity 2011) and to contribute to murine
chronic graft-vs.-host-disease (GVHD) (Flynn et al, Blood
2014). However, the role of TFH in immune reconstitution
and GVHD after human hematopoietic stem cell trans-
plantation (HSCT) has not been studied. Although TFH
function primarily in lymphoid tissues, these cells have also
been identiﬁed in peripheral blood. We analyzed fresh blood
samples from 98 patients obtained 2 to 97 months after
HSCT, and 11 Healthy Donors (HD). We deﬁned circulating
TFH (cTFH) as CD4+CD45RA-CXCR5+ T-cells. cTFH were then
subdivided into Th1, Th2, Th17 subsets (Th1: CXCR3+CCR6-,
Th2: CXCR3-CCR6-, Th17: CXCR3-CCR6+) as previously
described (Morita et al).
Analysis of patient peripheral blood revealed a progressive
increase in the cTFH absolute count from 2months to 2 years
after HSCT, which then reached a plateau. Nevertheless, cTFH
counts remained below normal values when compared with
HD throughout this period, and only reached normal levels 2
years after HSCT in parallel with recovery of total CD4+ Tcells
(Figure 1). In contrast, the fraction of cTFH within the CD4 T
cell compartment reached normal values within 6 months
after HSCT and remained stable.
To study the role of cTFH in cGVHD, we studied 71 patients
(excluding patients receiving prednisone >30mg/day, ritux-
imab or IL-2). In patients with active cGVHD, cTFH frequency
(median 8.78% vs. 10.5% of CD4+ T-cells, p¼0.0065) and cTFH
absolute counts (48.75 vs. 38.3/mL, p¼0.07) were decreased
compared with patients without cGVHD. cTFH subsets are
reported to have different functional capacities and this was
conﬁrmed by purifying and culturing each subset with naive
B-cells. In HD, we observed that only Th2 and Th17 subsets of
cTFH promoted B-cell IgG and IgM secretion (Figure 2). In
